



LKT Laboratories, Inc.

DCC-2036

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID D0808

CAS No. 1020172-07-9

Chemical Name

Synonym DCC2036, Rebastinib

Formula $C_{30}H_{28}FN_7O_3$

Formula Wt. 553.59

Melting Point

Purity $\geq 98\%$

Solubility DMSO 111 mg/mL (200.5 mM)


Ethanol 16 mg/mL (28.9 mM)

Water Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description DCC-2036 (rebastinib) is an Abl inhibitor that exhibits anticancer activity. In cellular models of chronic myelogenous leukemia (CML), rebastinib induces apoptosis and inhibits cell proliferation. Rebastinib binds the switch control pocket of Abl that is involved in conformational regulation of the kinase domain.



Bulk quantities available upon request

Product ID	Size
D0808	1 mg
D0808	5 mg
D0808	10 mg

References Shen Y, Shi X, Pan J. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFR α . PLoS One. 2013 Aug 29;8(8):e73059. PMID: 24009732.

Eide CA, Adrian LT, Tyner JW, et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABL T315I and exhibits a narrow resistance profile. Cancer Res. 2011 May 1;71(9):3189-95. PMID: 21505103.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.